0001209191-18-007843.txt : 20180206 0001209191-18-007843.hdr.sgml : 20180206 20180206162646 ACCESSION NUMBER: 0001209191-18-007843 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180205 FILED AS OF DATE: 20180206 DATE AS OF CHANGE: 20180206 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ros Matthew CENTRAL INDEX KEY: 0001673802 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35945 FILM NUMBER: 18577910 MAIL ADDRESS: STREET 1: C/O EPIZYME, INC. STREET 2: 400 TECHNOLOGY SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Epizyme, Inc. CENTRAL INDEX KEY: 0001571498 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 261349956 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 400 TECHNOLOGY SQUARE STREET 2: 4TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-229-5872 MAIL ADDRESS: STREET 1: 400 TECHNOLOGY SQUARE STREET 2: 4TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-02-05 0 0001571498 Epizyme, Inc. EPZM 0001673802 Ros Matthew C/O EPIZYME, INC. 400 TECHNOLOGY SQUARE CAMBRIDGE MA 02139 0 1 0 0 Chief Operating Officer Commons Stock, par value $0.0001 2018-02-05 4 M 0 72264 9.58 A 74867 D Commons Stock, par value $0.0001 2018-02-05 4 S 0 71745 16.6251 D 3122 D Common Stock, par value $0.0001 2018-02-05 4 S 0 519 17.20 D 2603 D Stock Option (Right to Buy) 9.58 2018-02-05 4 M 0 72264 0.00 D 2027-05-15 Common Stock 72264 0 D The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.20 per share to $17.15 per share, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. This option is fully vested. /s/ Adriana Sullivan, attorney-in-fact 2018-02-06